Benefits Plans - Azmacort® Aerosol Inhaler discontinued as of 12/31/2009
Azmacort® Aerosol Inhaler Discontinued
Effective December 31, 2009, Abbott will discontinue production of the Azmacort® Aerosol Inhaler. Azmacort®, generic name triamcinolone acetonide, is prescribed as a long-term therapy to control bronchial asthma attacks.
Patients using Azmacort® should contact their doctor for an alternate therapy. Flovent HFA and Pulmicort are the preferred corticosteroid inhalers covered by the University of Michigan Prescription Drug Plan. Azmacort® will remain available only until current supplies are depleted at pharmacies and wholesalers.
Abbott is discontinuing Azmacort® to comply with the international environmental protection agreement known as the Montreal Protocol, which calls for the elimination of CFC (chlorofluorocarbon) containing medical products, such as Azmacort.
Doctors may call Abbott Medical Information regarding the Azmacort® discontinuation, phone 1-800-633-9110 weekdays from 9:15 AM to 5:55 PM Eastern Time. The U.S. Food and Drug Administration (FDA) consumer inquiry line at 1-888-INFO-FDA (1-888-463-6332), website www.fda.gov also has information about the Azmacort® discontinuation.
The University of Michigan in its sole discretion may modify, amend, or terminate the benefits provided with respect to any individual receiving benefits, including active employees, retirees, and their dependents. Although the university has elected to provide these benefits this year, no individual has a vested right to any of the benefits provided. Nothing in these materials gives any individual the right to continued benefits beyond the time the university modifies, amends, or terminates the benefit. Anyone seeking or accepting any of the benefits provided will be deemed to have accepted the terms of the benefits programs and the university's right to modify, amend or terminate them.